Mediaboss Marketing

SNOWFLAKE SUMMIT, Las Vegas, June 14, 2022 (GLOBE NEWSWIRE) -- Dataiku, the platform for Everyday AI, today announced that it has been named the 2022 Machine Learning/AI Partner of the Year award winner by Snowflake, the Data Cloud company, for the second year in a row. This award was presented at Snowflake Summit 2022 The World of Data Collaboration.

Also at Snowflake Summit today, Dataiku received competency awards in financial services, healthcare life sciences, and retail and CPG for the depth of its Snowflake expertise and commitment to driving customer impact in these industries. The partnership between the two industry leaders has deepened in the past year, as the tandem supports a growing list of joint customers, including Ameritas, First Tech Federal Credit Union, Novartis, and, Monoprix.

Dataikus Everyday AI platform enables organizations of any size to deliver data, analytics, and AI projects in a collaborative, scalable environment that takes full advantage of their investment in Snowflake. In addition, the joint solution provides an easy-to-use, visual interface where coders and non-coders can securely team up to work with data in Snowflake to build production-ready data pipelines and data science projects, all in a single platform.

We are thrilled to be chosen as Snowflakes 2022 Machine Learning / AI Partner of the Year for the second year in a row, said David Tharp, SVP Ecosystems and Alliances at Dataiku. The power of our AI capability with the Snowflake Data Cloud platform is quickly shifting the landscape of intelligent cloud computing. We are providing value to our joint customers in minutes rather than months. In the past year, we have invested significantly in becoming the most tightly integrated machine learning / AI platform to Snowflake, and its very rewarding to see this value delivered to our customers.

"Snowflake and Dataiku's commitment to developing and delivering Everyday AI solutions is foundational to our shared mission of helping every organization benefit from a data-driven culture. Together with Dataiku, we are delivering on the promise of machine learning and AI for customers across industries," said Colleen Kapase, SVP of Worldwide Partnerships at Snowflake.

Combining Snowflakes Data Cloud with Dataikus end-to-end analytics and AI platform has been a game changer for our organization, greatly improving how we manage large datasets and complex analytics, said Jay Franklin, VP of Enterprise Data and Analytics at First Tech Federal Credit Union. As a credit union, we have a terrific opportunity to directly impact the lives of our members. By scaling and maturing our data science and analytics practices, we are making this a reality through member centricity and personalized, highly-relevant experiences and offerings.

Dataikus integrated access with Snowpark for Python

A year after announcing its integration with Snowflakes Snowpark and Java user-defined functions (UDFs), Dataiku has also integrated access to Snowpark for Python, enabling Python coders and developers to work with familiar tools, packages, and libraries. Now, coders can focus on innovation while avoiding manual tasks and dependencies.

The new and existing integrations with Snowflake allow users to accomplish the following:

These integrations and more give customers the speed, scale, and security of Snowflakes high-performance engine with Dataikus platform for Everyday AI.

Resources

See the original post:
Dataiku Named Snowflake Machine Learning/AI Partner of the Year Award for the 2nd Year in a Row - GlobeNewswire

Of course, transparency and privacy concerns are significant, she notes, but if the information from our public health care system benefits everyone, is it inefficient to ask for consent for every use?

On the other hand, cybersecurity is another essential consideration, as weve come to learn that there are a lot of malevolent actors out there, says Miller Olafsson, with the potential ability to hack into centralized systems as part of a ransomware attack or other threat.

Even in its more basic uses, the potential of AI and machine learning is enormous. But the tricky part of using it in the health care sector is the need to have access to incredible amounts of data while at the same time understanding the sensitive nature of the data collected.

For artificial intelligence to be used in systems, procedures, or devices, you need access to data, and getting that data, particularly personal health information, is very challenging, says Carole Piovesan, managing partner at INQ Law in Toronto.

She points to the developing legal frameworks in Europe and North America for artificial intelligence and privacy legislation more generally. Lawyers working with start-up companies or health care organizations to build AI systems must help them stay within the parameters of existing laws, says Piovesan, and provide guidance on best practices for whatever may come down the line and help them deal with the potential risks.

Here is the original post:
Advances in AI and machine learning could lead to better health care: lawyers - Lexpert

Machine learning can enable positive change in society, says Adam Benzion, Chief Experience Officer at Edge Impulse. Read on to learn how the company is preventing unethical uses of its ML/AI development platform.

Machine learning can enable positive change in society, says Adam Benzion, Chief Experience Officer at Edge Impulse. Read on to learn how the company is preventing unethical uses of its ML/AI development platform.

Priscilla Haring-Kuipers: What Ethics in Electronics are you are working on?

Adam Benzion: At Edge Impulse, we try to connect our work to doing good in the world as a core value to our culture and operating philosophy. Our founders, Zach Shelby and Jan Jongboom define this as Machine learning can enable positive change in society, and we are dedicated to support applications for good. This is fundamental to what and how we do things. We invest our resources to support initiatives like UN Covid-19 Detect & Protect, Data Science Africa, and wildlife conservation with Smart Parks, Wildlabs, and ConservationX.

This also means we have a responsibility to prevent unethical uses of our ML/AI development platform. When Edge Impulse launched in January 2020, we decided to require a Responsible AI Licensefor our users, which prevents use for criminal purposes, surveillance, or harmful military or police applications. We have had a couple of cases where we have turned down a project that were not compatible with this license. There are also many positive uses for ML in governmental and defense applications, which we do support as compatible with our values.

We also joined 1% for the Planet, pledging to donate 1% of our revenue to support nonprofit organizations focused on the environment. I personally lead an initiative that focuses on elephant conservation where we have partnered with an organization called Smart Parks and helped developed a new AI-powered tracking collar that can last for eight years and be used to understand how the elephants communicate with each other. This is now deployed in parks across Mozambique.

Haring-Kuipers: What is the most important ethical question in your field?

Benzion: There are a lot of ethical issues with AI being used in population control, human recognition and tracking, let alone AI-powered weaponry. Especially where we touch human safety and dignity, AI-powered applications must be carefully evaluated, legislated and regulated. We dream of automation, fun magical experiences, and human-assisted technologies that do things better, faster and at a lesser cost. Thats the good AI dream, and thats what we all want to build. In a perfect world, we should all be able to vote on the rules and regulations that govern AI.

Haring-Kuipers: What would you like to include in an Electronics Code of Ethics?

Benzion: We need to look at how AI impacts human rights and machine accountability aka, when AI-powered machines fail, like in the case of autonomous driving, who takes the blame? Without universal guidelines to support us, it is up to every company in this field to find its core values and boundaries so we can all benefit from this exciting new wave.

Haring-Kuipers: An impossible choice ... The most important question before building anything is? A) Should I build this? B) Can I build this? C) How can I build this?

Benzion: A. Within reason, you can build almost anything, so ask yourself: Is the effort vs. outcome worth your precious time?

Priscilla Haring-Kuipers writes about technology from a social science perspective. She is especially interested in technology supporting the good in humanity and a firm believer in effect research. She has an MSc in Media Psychology and makes This Is Not Rocket Science happen.

Go here to see the original:
Machine Learning to Enable Positive Change An Interview with Adam Benzion - Elektor

Chicago, June 15, 2022 (GLOBE NEWSWIRE) -- According to the new market research report AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech, CROs) - Global Forecasts to 2027, published by MarketsandMarkets, the global Artificial Intelligence in Drug Discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period.

Browse in-depth TOC on Artificial Intelligence (AI) in Drug Discovery Market177 Tables 33 Figures 198 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and partnerships, On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

Services segment is expected to grow at the highest rate during the forecast period.

Based on offering, the AI in drug discovery market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in drug discovery services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment.

Machine learning technology segment accounted for the largest share of the global AI in drug discovery market.

Based on technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning. reinforcement learning, unsupervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446

The immuno-oncology application segment accounted for the largest share of the AI in drug discovery market in 2021.

On the basis of application, the AI in drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular diseases, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs. The neurodegenerative diseases segment is estimated to register the highest CAGR during the forecast period. The role of AI in resolving existing complexities in neurological drug development and strategic collaborations between pharmaceutical companies & solution providers are the key factors responsible for the high growth rate of the neurodegenerative diseases segment.

Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in drug discovery market.

On the basis of end user, the AI in drug discovery market is segmented into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. The pharmaceutical & biotechnology companies segment accounted for the largest market share of AI in drug discovery market, in 2021, while the research centers and academic & government institutes segment is projected to register the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is driving the growth of this end-user segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=151193446

North America is expected to dominate the Artificial Intelligence in Drug Discovery Market in 2022.

North America accounted for the largest share of the global AI in drug discovery market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Top Key Players in Artificial Intelligence in Drug Discovery Market are:

Players in AI in Drug Discovery Market adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Browse Adjacent Markets:Healthcare IT Market Research Reports & Consulting

Browse Related Reports:

Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html

Artificial Intelligence In Genomics Market by Offering (Software, Services),Technology (Machine Learning, Computer Vision), Functionality (Genome Sequencing, Gene Editing), Application (Diagnostics), End User (Pharma, Research)-Global Forecasts to 2025https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-in-genomics-market-36649899.html

Continue reading here:
Artificial Intelligence in Drug Discovery Market worth $4.0 billion by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire

Accel Solutions and Veego today announced the integration of Veego's Artificial Intelligence and machine learning solution with Bezeq, Israel's largest Telecom. The integration will enhance Bezeq's ability to provide its subscribers with improved Internet quality of experience and mitigate network malfunctions. Bezeq will integrate Veego's solution in their consumer line of Be-Routers. The Veego solution provides Bezeq the ability to identify and mitigate connectivity malfunctions remotely, attain a broad overview of the network and improve the overall experience for its customers.

Niv Berkner, Head of Services and Product Innovation at Bezeq indicated "I have no doubt that the integration of the Veego solution in our Be-Routers will allow us to provide our customers an optimal quality of experience. The Veego solution will allow us to understand the interaction between all the devices connected in the home, and as such, provide Bezeq the ability to identify, anticipate and mitigate network related malfunctions remotely, without the customers involvement and/or being aware."

"Veego provides ISPs and CSPs the ability to leverage data and provide them with insights that alleviate churn, while constantly improving the customer experience." outlined Amir Kotler, Veego's CEO.

"The integration of Veego's AI and ML capabilities enable Telcos to actually experience what the customer experiences when he has an internet malfunction that disrupts a healthy Internet process," Kotler added "Veego's solution enables ISP to predict the issue, resolve it in autonomic ways and as a result, improves operational efficiency, increases revenues and reduces churn."

Ronen Shor, CEO of Accel Solutions stated, "The Bezeq - Veego agreement is another step in our continuous enhancement efforts on the products sold to Bezeq and a significant technological upgrade offered by Bezeq to its customers. Accel Solutions considers Veego as a strategic partner with tremendous potential in the international market.

Source:https://accelsolutionsllc.com/

Go here to read the rest:
Veegos Artificial Intelligence and Machine Learning Solution Integrated with Israels Largest Telecom - AZoRobotics